Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

SOX2 in development and cancer biology.

Novak D, Hüser L, Elton JJ, Umansky V, Altevogt P, Utikal J.

Semin Cancer Biol. 2019 Aug 11. pii: S1044-579X(18)30185-8. doi: 10.1016/j.semcancer.2019.08.007. [Epub ahead of print] Review.

2.

Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma.

Gao M, Bai H, Jethava Y, Wu Y, Zhu Y, Yang Y, Xia J, Cao H, Franqui-Machin R, Nadiminti K, Thomas GS, Salama ME, Altevogt P, Bishop G, Tomasson M, Janz S, Shi J, Chen L, Frech I, Tricot G, Zhan F.

J Natl Cancer Inst. 2019 Aug 12. pii: djz159. doi: 10.1093/jnci/djz159. [Epub ahead of print]

PMID:
31406992
3.

Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.

Fleming V, Hu X, Weller C, Weber R, Groth C, Riester Z, Hüser L, Sun Q, Nagibin V, Kirschning C, Bronte V, Utikal J, Altevogt P, Umansky V.

Cancer Res. 2019 Sep 15;79(18):4715-4728. doi: 10.1158/0008-5472.CAN-19-0053. Epub 2019 Jul 23.

PMID:
31337655
4.

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies.

Hüser L, Altevogt P, Utikal J.

Oncotarget. 2019 Mar 1;10(18):1662-1663. doi: 10.18632/oncotarget.26718. eCollection 2019 Mar 1. No abstract available.

5.

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.

Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V.

Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9. Review.

PMID:
30413826
6.

Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Müller-Holzner E, Bode PK, Tischler V, Altevogt P.

BMC Cancer. 2018 Oct 29;18(1):1047. doi: 10.1186/s12885-018-4928-y.

7.

Targeting SOX2 in anticancer therapy.

Hüser L, Novak D, Umansky V, Altevogt P, Utikal J.

Expert Opin Ther Targets. 2018 Dec;22(12):983-991. doi: 10.1080/14728222.2018.1538359. Epub 2018 Oct 26. Review.

PMID:
30366514
8.

Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.

Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, Shahaj E, Sulsenti R, Vergani E, Filipazzi P, De Laurentiis A, Lalli L, Di Guardo L, Patuzzo R, Vergani B, Casiraghi E, Cossa M, Gualeni A, Bollati V, Arienti F, De Braud F, Mariani L, Villa A, Altevogt P, Umansky V, Rodolfo M, Rivoltini L.

J Clin Invest. 2018 Dec 3;128(12):5505-5516. doi: 10.1172/JCI98060. Epub 2018 Nov 5.

9.

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.

Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V.

Front Immunol. 2018 Jun 11;9:1310. doi: 10.3389/fimmu.2018.01310. eCollection 2018. Review.

10.

SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.

Hüser L, Sachindra S, Granados K, Federico A, Larribère L, Novak D, Umansky V, Altevogt P, Utikal J.

Int J Cancer. 2018 Dec 15;143(12):3131-3142. doi: 10.1002/ijc.31609. Epub 2018 Oct 16.

PMID:
29905375
11.

Extracellular vesicles from human saliva promote hemostasis by delivering coagulant tissue factor to activated platelets.

Yu Y, Gool E, Berckmans RJ, Coumans FAW, Barendrecht AD, Maas C, van der Wel NN, Altevogt P, Sturk A, Nieuwland R.

J Thromb Haemost. 2018 Jun;16(6):1153-1163. doi: 10.1111/jth.14023. Epub 2018 May 17.

PMID:
29658195
12.

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V.

Front Immunol. 2018 Mar 2;9:398. doi: 10.3389/fimmu.2018.00398. eCollection 2018. Review.

13.

Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.

Reimer D, Boesch M, Wolf D, Marth C, Sopper S, Hatina J, Altevogt P, Parson W, Hackl H, Zeimet AG.

Int J Cancer. 2018 Apr 15;142(8):1640-1651. doi: 10.1002/ijc.31186. Epub 2017 Dec 14.

14.

CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions.

Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze TJ, Razon H, Hawila E, Wildbaum G, Utikal J, Karin N, Umansky V.

Cancer Res. 2018 Jan 1;78(1):157-167. doi: 10.1158/0008-5472.CAN-17-0348. Epub 2017 Oct 31.

15.

TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.

Ratz L, Laible M, Kacprzyk LA, Wittig-Blaich SM, Tolstov Y, Duensing S, Altevogt P, Klauck SM, Sültmann H.

Oncotarget. 2017 Apr 11;8(15):25115-25130. doi: 10.18632/oncotarget.15931.

16.

Procoagulant extracellular vesicles in amniotic fluid.

Hell L, Wisgrill L, Ay C, Spittler A, Schwameis M, Jilma B, Pabinger I, Altevogt P, Thaler J.

Transl Res. 2017 Jun;184:12-20.e1. doi: 10.1016/j.trsl.2017.01.003. Epub 2017 Feb 4.

17.

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.

Sinn HP, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, Lakis S, Veltrup E, Altevogt P, Eidt S, Wirtz RM, Marmé F.

BMC Cancer. 2017 Feb 13;17(1):124. doi: 10.1186/s12885-017-3111-1.

18.

L1CAM in the Early Enteric and Urogenital System.

Pechriggl EJ, Concin N, Blumer MJ, Bitsche M, Zwierzina M, Dudas J, Koziel K, Altevogt P, Zeimet AG, Fritsch H.

J Histochem Cytochem. 2017 Jan;65(1):21-32. doi: 10.1369/0022155416677241. Epub 2016 Nov 12.

19.

Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface.

Sammar M, Siwetz M, Meiri H, Fleming V, Altevogt P, Huppertz B.

Histochem Cell Biol. 2017 May;147(5):565-574. doi: 10.1007/s00418-016-1531-7. Epub 2016 Dec 23.

PMID:
28012129
20.

Myeloid-derived suppressor cells and tumor escape from immune surveillance.

Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, Utikal J.

Semin Immunopathol. 2017 Apr;39(3):295-305. doi: 10.1007/s00281-016-0597-6. Epub 2016 Oct 27. Review.

PMID:
27787613
21.

Evaluating L1CAM expression in human endometrial cancer using qRT-PCR.

Notaro S, Reimer D, Duggan-Peer M, Fiegl H, Wiedermair A, Rössler J, Altevogt P, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 28;7(26):40221-40232. doi: 10.18632/oncotarget.9574.

22.

L1-CAM is commonly expressed in testicular germ cell tumours.

Fankhauser CD, Bode PK, Hermanns T, Sander S, Beyer J, Sulser T, Altevogt P, Moch H, Tischler V.

J Clin Pathol. 2016 May;69(5):460-2. doi: 10.1136/jclinpath-2016-203603. Epub 2016 Mar 1. No abstract available.

23.

L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.

Geels YP, Pijnenborg JM, Gordon BB, Fogel M, Altevogt P, Masadah R, Bulten J, van Kempen LC, Massuger LF.

Pathol Oncol Res. 2016 Oct;22(4):863-8. doi: 10.1007/s12253-016-0047-8. Epub 2016 Feb 18.

24.

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.

Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin N, Altevogt P, Marth C, Zeimet AG.

BMC Cancer. 2016 Feb 15;16:102. doi: 10.1186/s12885-016-2135-2.

25.

Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients.

Majores M, Schindler A, Fuchs A, Stein J, Heukamp L, Altevogt P, Kristiansen G.

BMC Clin Pathol. 2015 Nov 16;15:19. doi: 10.1186/s12907-015-0019-z. eCollection 2015.

26.

Single-Molecule Localization Microscopy allows for the analysis of cancer metastasis-specific miRNA distribution on the nanoscale.

Oleksiuk O, Abba M, Tezcan KC, Schaufler W, Bestvater F, Patil N, Birk U, Hafner M, Altevogt P, Cremer C, Allgayer H.

Oncotarget. 2015 Dec 29;6(42):44745-57. doi: 10.18632/oncotarget.6297.

27.

Extracellular Vesicles from Ovarian Carcinoma Cells Display Specific Glycosignatures.

Gomes J, Gomes-Alves P, Carvalho SB, Peixoto C, Alves PM, Altevogt P, Costa J.

Biomolecules. 2015 Aug 4;5(3):1741-61. doi: 10.3390/biom5031741.

28.

Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment.

Ridder K, Sevko A, Heide J, Dams M, Rupp AK, Macas J, Starmann J, Tjwa M, Plate KH, Sültmann H, Altevogt P, Umansky V, Momma S.

Oncoimmunology. 2015 Mar 19;4(6):e1008371. eCollection 2015 Jun.

29.

L1CAM in human cancer.

Altevogt P, Doberstein K, Fogel M.

Int J Cancer. 2016 Apr 1;138(7):1565-76. doi: 10.1002/ijc.29658. Epub 2015 Aug 25. Review.

30.

A novel method for measuring cellular antibody uptake using imaging flow cytometry reveals distinct uptake rates for two different monoclonal antibodies targeting L1.

Hazin J, Moldenhauer G, Altevogt P, Brady NR.

J Immunol Methods. 2015 Aug;423:70-7. doi: 10.1016/j.jim.2015.04.024. Epub 2015 May 9.

PMID:
25967950
31.

Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.

Piesche M, Ho VT, Kim H, Nakazaki Y, Nehil M, Yaghi NK, Kolodin D, Weiser J, Altevogt P, Kiefel H, Alyea EP, Antin JH, Cutler C, Koreth J, Canning C, Ritz J, Soiffer RJ, Dranoff G.

Clin Cancer Res. 2015 Mar 1;21(5):1010-8. doi: 10.1158/1078-0432.CCR-14-1956. Epub 2014 Dec 23.

32.

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.

Doberstein K, Milde-Langosch K, Bretz NP, Schirmer U, Harari A, Witzel I, Ben-Arie A, Hubalek M, Müller-Holzner E, Reinold S, Zeimet AG, Altevogt P, Fogel M.

BMC Cancer. 2014 Dec 15;14:958. doi: 10.1186/1471-2407-14-958.

33.

Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.

Doberstein K, Harter PN, Haberkorn U, Bretz NP, Arnold B, Carretero R, Moldenhauer G, Mittelbronn M, Altevogt P.

Int J Cancer. 2015 Mar 1;136(5):E326-39. doi: 10.1002/ijc.29222. Epub 2014 Sep 25.

34.

miR-21-3p is a positive regulator of L1CAM in several human carcinomas.

Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, Müller-Holzner E, Reimer D, Zeimet AG, Altevogt P.

Cancer Lett. 2014 Nov 28;354(2):455-66. doi: 10.1016/j.canlet.2014.08.020. Epub 2014 Aug 19.

PMID:
25149066
35.

Lack of CD24 expression in mice reduces the number of leukocytes in the colon.

Bretz NP, Salnikov AV, Doberstein K, Garbi N, Kloess V, Joumaa S, Naumov I, Boon L, Moldenhauer G, Arber N, Altevogt P.

Immunol Lett. 2014 Sep;161(1):140-8. doi: 10.1016/j.imlet.2014.06.004. Epub 2014 Jun 20.

PMID:
24956310
36.

Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation.

Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Del Turco D, Starmann J, Macas J, Karpova D, Devraj K, Depboylu C, Landfried B, Arnold B, Plate KH, Höglinger G, Sültmann H, Altevogt P, Momma S.

PLoS Biol. 2014 Jun 3;12(6):e1001874. doi: 10.1371/journal.pbio.1001874. eCollection 2014 Jun. Erratum in: PLoS Biol. 2018 Mar 12;16(3):e1002623.

37.

Combined targeting of TGF-β1 and integrin β3 impairs lymph node metastasis in a mouse model of non-small-cell lung cancer.

Salvo E, Garasa S, Dotor J, Morales X, Peláez R, Altevogt P, Rouzaut A.

Mol Cancer. 2014 May 19;13:112. doi: 10.1186/1476-4598-13-112.

38.

Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.

Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S, Cerwenka A.

Cancer Res. 2014 Jul 1;74(13):3429-40. doi: 10.1158/0008-5472.CAN-13-3017. Epub 2014 Apr 29.

39.

Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation.

Altevogt P, Bretz NP, Ridinger J, Utikal J, Umansky V.

Semin Cancer Biol. 2014 Oct;28:51-7. doi: 10.1016/j.semcancer.2014.04.008. Epub 2014 Apr 24. Review.

PMID:
24769223
40.

L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression.

Grage-Griebenow E, Jerg E, Gorys A, Wicklein D, Wesch D, Freitag-Wolf S, Goebel L, Vogel I, Becker T, Ebsen M, Röcken C, Altevogt P, Schumacher U, Schäfer H, Sebens S.

Mol Oncol. 2014 Jul;8(5):982-97. doi: 10.1016/j.molonc.2014.03.001. Epub 2014 Apr 2.

41.

Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.

Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P.

Oncotarget. 2014 Jan 30;5(2):462-72.

42.

L1 cell adhesion molecule as a potential therapeutic target in murine models of endometriosis using a monoclonal antibody approach.

Silveira CG, Finas D, Hunold P, Köster F, Stroschein K, Canny GO, Moldenhauer G, Altevogt P, Rody A, Hornung D.

PLoS One. 2013 Dec 4;8(12):e82512. doi: 10.1371/journal.pone.0082512. eCollection 2013.

43.

A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms.

Fogel M, Harari A, Müller-Holzner E, Zeimet AG, Moldenhauer G, Altevogt P.

Int J Biol Markers. 2014 Jun 25;29(2):e180-3. doi: 10.5301/jbm.5000055.

PMID:
24242293
44.

Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling.

Bretz NP, Ridinger J, Rupp AK, Rimbach K, Keller S, Rupp C, Marmé F, Umansky L, Umansky V, Eigenbrod T, Sammar M, Altevogt P.

J Biol Chem. 2013 Dec 20;288(51):36691-702. doi: 10.1074/jbc.M113.512806. Epub 2013 Nov 13.

45.

Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth.

Weinspach D, Seubert B, Schaten S, Honert K, Sebens S, Altevogt P, Krüger A.

Clin Exp Metastasis. 2014 Jan;31(1):87-100. doi: 10.1007/s10585-013-9613-6. Epub 2013 Sep 4.

PMID:
24002299
46.

Exosomes as a potential tool for a specific delivery of functional molecules.

Nazarenko I, Rupp AK, Altevogt P.

Methods Mol Biol. 2013;1049:495-511. doi: 10.1007/978-1-62703-547-7_37.

PMID:
23913240
47.

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.

J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763.

PMID:
23781004
48.

Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Müller-Holzner E, Bode PK, Tischler V, Altevogt P.

BMC Cancer. 2013 Mar 26;13:156. doi: 10.1186/1471-2407-13-156. Erratum in: BMC Cancer. 2018 Oct 29;18(1):1047.

49.

Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas.

Salnikov AV, Bretz NP, Perne C, Hazin J, Keller S, Fogel M, Herr I, Schlange T, Moldenhauer G, Altevogt P.

Br J Cancer. 2013 Apr 16;108(7):1449-59. doi: 10.1038/bjc.2013.102. Epub 2013 Mar 19.

50.

CD24 polymorphisms in breast cancer: impact on prognosis and risk.

Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, Schneeweiss A, Burwinkel B, Jäger D, Flesch-Janys D, Chang-Claude J, Marmé F.

Breast Cancer Res Treat. 2013 Feb;137(3):927-37. doi: 10.1007/s10549-012-2325-9. Epub 2013 Jan 13.

PMID:
23314606

Supplemental Content

Loading ...
Support Center